What is Lantern Pharma Operating Cash Flow per Share?
Lantern Pharma's operating cash flow per share for the
three
months ended in Mar. 2024 was $-0.29.
Lantern Pharma's operating cash flow per share for the trailing twelve months (TTM) ended in Mar. 2024 was $-1.26.
During the past 3 years, the average Operating Cash Flow per Share Growth Rate was -0.30% per year.
During the past 5 years, the average Operating Cash Flow per Share Growth Rate was -43.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.
The historical rank and industry rank for Lantern Pharma's Operating Cash Flow per Share or its related term are showing as below:
LTRN'
s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -67.9 Med: -51 Max: -0.3
Current: -0.3
During the past 6 years, Lantern Pharma's highest 3-Year average Operating Cash Flow per Share Growth Rate was -0.30% per year. The lowest was -67.90% per year. And the median was -51.00% per year.
Lantern Pharma Operating Cash Flow per Share Historical Data
The historical data trend for Lantern Pharma's Operating Cash Flow per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lantern Pharma Operating Cash Flow per Share Chart
|
Lantern Pharma Annual Data
|
|
Trend |
Dec18 |
Dec19 |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
| Operating Cash Flow per Share |
|
Get a 7-Day Free Trial
|
-0.34 |
-1.31 |
-0.97 |
-1.18 |
-1.32 |
|
Lantern Pharma Quarterly Data
|
|
Jun19 |
Sep19 |
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
Mar24 |
| Operating Cash Flow per Share |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
|
|
|
|
-0.35 |
-0.33 |
-0.33 |
-0.31 |
-0.29 |
Competitive Comparison of Lantern Pharma's Operating Cash Flow per Share
For the Biotechnology subindustry, Lantern Pharma's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lantern Pharma's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lantern Pharma's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Lantern Pharma's Price-to-Operating-Cash-Flow falls into.
Lantern Pharma Operating Cash Flow per Share Calculation
Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.
Lantern Pharma's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2023 is calculated as
Lantern Pharma's Operating Cash Flow per Share for the quarter that ended in Dec. 2023 is calculated as
Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.26
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lantern Pharma (Lantern Pharma) Business Description
Traded in Other Exchanges
N/A
Address
1920 McKinney Avenue, 7th Floor, Dallas, TX, USA, 75201
Lantern Pharma is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.
Executives
| Leslie W. Kreis |
10 percent owner |
1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107 |
| Bios Fund I, Lp |
10 percent owner |
1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107 |
| Bios Fund I Qp, Lp |
10 percent owner |
1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107 |
| Cavu Management, Lp |
10 percent owner |
1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107 |
| Bios Advisors Gp, Llc |
10 percent owner |
1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107 |
| Bios Capital Management, Lp |
10 percent owner |
1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107 |
| Cavu Advisors, Llc |
10 percent owner |
1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107 |
| Bp Directors, Lp |
10 percent owner |
1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107 |
| Bios Fund Ii Nt, Lp |
10 percent owner |
1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107 |
| Bios Fund Ii Qp, Lp |
10 percent owner |
1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107 |
| Bios Fund Ii, Lp |
10 percent owner |
1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107 |
| Bios Equity Partners Ii, Lp |
10 percent owner |
1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107 |
| Bios Equity Partners, Lp |
10 percent owner |
1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107 |
| Fletcher Aaron G.l. |
10 percent owner |
40 GUEST STREET, BOSTON MA 02135 |
| Maria-luisa Maccecchini |
director |
1223 FOXGLOVE LANE, WEST CHESTER PA 19380 |
Lantern Pharma (Lantern Pharma) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LTRN has been successfully added to your